Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
Public ClinicalTrials.gov record NCT02063997. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Active and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine whether arhalofenate is effective in preventing flares and reducing serum uric acid in gout patients.
Study identification
- NCT ID
- NCT02063997
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 248 participants
Conditions and interventions
Conditions
Interventions
- Arhalofenate 600 mg Drug
- Allopurinol 300 mg Drug
- Colchicine 0.6 mg Drug
- Placebo Drug
- Arhalofenate 800 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2014 (Type not available)
- Primary completion
- Jan 2015 (Actual)
- Completion
- Jan 2015 (Actual)
- Last update posted
- Jan 29, 2018
2014 – 2015
United States locations
- U.S. sites
- 52
- U.S. states
- 28
- U.S. cities
- 52
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Scottsdale | Arizona | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | El Cajon | California | — | — |
| Not listed | Long Beach | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Washington D.C. | District of Columbia | — | — |
| Not listed | Clearwater | Florida | — | — |
| Not listed | DeLand | Florida | — | — |
| Not listed | Jupiter | Florida | — | — |
| Not listed | New Port Richey | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Palm Harbor | Florida | — | — |
| Not listed | St. Petersburg | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Honolulu | Hawaii | — | — |
| Not listed | Boise | Idaho | — | — |
| Not listed | Brownsburg | Indiana | — | — |
| Not listed | Bowling Green | Kentucky | — | — |
| Not listed | Elizabethtown | Kentucky | — | — |
| Not listed | Louisville | Kentucky | — | — |
| Not listed | Owensboro | Kentucky | — | — |
| Not listed | Hagerstown | Maryland | — | — |
| Not listed | Olive Branch | Mississippi | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Missoula | Montana | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Brooklyn | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Greensboro | North Carolina | — | — |
| Not listed | Hickory | North Carolina | — | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | Salisbury | North Carolina | — | — |
| Not listed | Winston-Salem | North Carolina | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Johnstown | Pennsylvania | — | — |
| Not listed | Wyomissing | Pennsylvania | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Greer | South Carolina | — | — |
| Not listed | Summerville | South Carolina | — | — |
| Not listed | Bristol | Tennessee | — | — |
| Not listed | Jackson | Tennessee | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | West Jordan | Utah | — | — |
| Not listed | Spokane | Washington | — | — |
| Not listed | Clarksburg | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02063997, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 29, 2018 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02063997 live on ClinicalTrials.gov.